Table 1 Correlation analysis between pBADS99/BAD levels and clinicopathological features of PDAC patients.

From: Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRASG12D-mutant pancreatic ductal adenocarcinoma

Cohort

Total (N)

High (%)

Low (%)

P-value

Gender

>0.999

 Male

24

71

29

 Female

31

71

29

Age

   

>0.999

 <60

21

71

29

 >=60

34

71

29

Diameter

0.006**

 <=4

33

64

36

 >4

22

82

18

Grade

0.455

 1

6

67

33

 2

16

75

25

 3

33

70

30

TNM

0.004**

 I

24

62.5

37.5

 II

15

80

20

 III

6

83

17

 IV

10

70

30

Lymph node metastasis

0.876

 Yes

18

72

28

 No

37

70

30

Distant metastasis

0.539

 Yes

9

67

33

 No

46

72

28

  1. *P < 0.05, **P < 0.01, and ***P < 0.001. An immunoreactive score (IRS) ≥2 was categorized as high pBADS99/BAD and an IRS <2 was categorized as low pBADS99/BAD in the PDAC patient cohort.
Back to article page